Scalper1 News
CVS Health (CVS) on Monday said it would select Gilead Sciences’ (GILD) Sovaldi and Harvoni as the exclusive treatments for hepatitis C patients who use some of its benefit plans, the latest development in what could become a price war among hepatitis C drugmakers. The decision, which takes hold Wednesday, comes after Express Scripts’ (ESRX) move last month to dump Gilead’s drugs from its preferred formulary list for genotype 1 hepatitis C Scalper1 News
Scalper1 News